Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Successful treatment of incidental prostate cancer by radical transurethral resection of prostate cancer.

Morita M, Matsuura T.

Clin Genitourin Cancer. 2013 Jun;11(2):94-9. doi: 10.1016/j.clgc.2012.09.012. Epub 2012 Nov 6.

PMID:
23137625
2.

Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery.

Gakis G, Schilling D, Bedke J, Sievert KD, Stenzl A.

BJU Int. 2010 Feb;105(4):468-71. doi: 10.1111/j.1464-410X.2009.08739.x. Epub 2009 Jul 7.

3.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
4.

[Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].

Heidenreich A, Ohlmann C, Ozgür E, Engelmann U.

Urologe A. 2006 Apr;45(4):474-81. German.

PMID:
16465521
5.

Endoscopic extraperitoneal radical prostatectomy after previous transurethral resection of prostate: oncologic and functional outcomes of 100 cases.

Do M, Haefner T, Liatsikos E, Kallidonis P, Hicks J, Dietel A, Horn LC, Rabenalt R, Stolzenburg JU.

Urology. 2010 Jun;75(6):1348-52. doi: 10.1016/j.urology.2009.09.009. Epub 2009 Nov 14.

PMID:
19914701
6.

Critical analysis of salvage radical prostatectomy in the management of radioresistant prostate cancer.

Seabra D, Faria E, Dauster B, Rodrigues G, Fava G.

Int Braz J Urol. 2009 Jan-Feb;35(1):43-8.

7.

Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.

Thüroff S, Chaussy C.

J Urol. 2013 Aug;190(2):702-10. doi: 10.1016/j.juro.2013.02.010. Epub 2013 Feb 13.

PMID:
23415962
8.

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H.

Eur Urol. 1999;36(1):21-30.

PMID:
10364651
9.

Open radical retropubic prostatectomy gives favourable surgical and functional outcomes after transurethral resection of the prostate.

Palisaar JR, Wenske S, Sommerer F, Hinkel A, Noldus J.

BJU Int. 2009 Sep;104(5):611-5. doi: 10.1111/j.1464-410X.2009.08474.x. Epub 2009 Mar 4.

10.

Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era.

Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G.

Urology. 2012 Mar;79(3):626-31. doi: 10.1016/j.urology.2011.09.051. Epub 2012 Jan 13.

PMID:
22245303
11.

Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.

Pfeiffer D, Berger J, Gross AJ.

BJU Int. 2012 Dec;110(11):1702-7. doi: 10.1111/j.1464-410X.2012.11375.x. Epub 2012 Aug 29.

12.

Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.

Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M.

Can J Urol. 2009 Oct;16(5):4813-9.

PMID:
19796456
13.
14.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
15.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

16.

Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.

Ploussard G, Masson-Lecomte A, Beauval JB, Ouzzane A, Bonniol R, Buge F, Fadli S, Rouprêt M, Rebillard X, Gaschignard N, Pfister C, Villers A, Soulié M, Salomon L; Prostate Cancer Committee of the French Association of Urology..

Urology. 2011 Sep;78(3):607-13. doi: 10.1016/j.urology.2011.05.021. Epub 2011 Jul 23.

PMID:
21783233
17.

Palliative transurethral resection of the prostate: functional outcome and impact on survival.

Marszalek M, Ponholzer A, Rauchenwald M, Madersbacher S.

BJU Int. 2007 Jan;99(1):56-9. Epub 2006 Oct 11.

19.

HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.

Asimakopoulos AD, Miano R, Virgili G, Vespasiani G, Finazzi Agrò E.

Urol Oncol. 2012 Sep;30(5):577-83. doi: 10.1016/j.urolonc.2010.08.019. Epub 2011 Feb 2.

PMID:
21292508
20.

Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.

Geinitz H, Riegel MG, Thamm R, Astner ST, Lewerenz C, Zimmermann F, Molls M, Nieder C.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1930-7. doi: 10.1016/j.ijrobp.2011.03.003. Epub 2011 Apr 22.

PMID:
21514736

Supplemental Content

Support Center